For the review to withstand the necessary scrutiny it will face upon publication, the FDA must prioritize robust, real-world data sources.
The FDA's data on mifepristone can't be trusted — here's why
Political Leaning Analysis
Score: 0.00 •
Center / Neutral
Left
Center
Right
Story Timeline
Thu 13:00 - The Hill
The FDA's data on mifepristone can't be trusted — here's why